Adult minimal-change disease: clinical characteristics, treatment, and outcomes.
about
Chinese herbal medicine Huangqi type formulations for nephrotic syndromeTreatment of nephrotic syndrome with adrenocorticotropic hormone (ACTH) gelRelapse of minimal change disease following infection with the 2009 pandemic influenza (H1N1) virus.Syncope in a patient with minimal change disease without nephrotic-range proteinuria.Corticosteroids vs. corticosteroids plus cycloporin A in adult minimal changes diseaseAmerican Society of Nephrology quiz and questionnaire 2013: glomerulonephritis.Steroid Pulse Therapy for De Novo Minimal Change Disease During PregnancyPotential urine proteomics biomarkers for primary nephrotic syndrome.IgA nephropathy with minimal change disease.Comparison of methylprednisolone plus prednisolone with prednisolone alone as initial treatment in adult-onset minimal change disease: a retrospective cohort studyThe efficacy of rituximab in adult frequently relapsing minimal change disease.A higher frequency of CD4⁺CXCR5⁺ T follicular helper cells in adult patients with minimal change disease.Kidney biopsy in patients with glomerulonephritis: is the earlier the better?Proteomic profiling identifies haptoglobin as a potential serum biomarker for steroid-resistant nephrotic syndrome.Relationship between serum soluble urokinase plasminogen activator receptor level and steroid responsiveness in FSGSNon-immunologic actions of calcineurin inhibitors in proteinuric kidney diseases.The accumulated experience with the use of mycophenolate mofetil in primary glomerulonephritis.Rifampicin-induced minimal change disease is improved after cessation of rifampicin without steroid therapy.Sustained complete remission of steroid- and cyclophosphamide-resistant minimal-change disease with a single course of rituximab therapyEfficacy of cyclosporine combination therapy for new-onset minimal change nephrotic syndrome in adultsMinimal-change disease in adolescents and adults: epidemiology and therapeutic response.A series of patients with minimal change nephropathy treated with rituximab during adolescence and adulthood.Angiopoietin-Like-4, a Potential Target of Tacrolimus, Predicts Earlier Podocyte Injury in Minimal Change Disease.Association of Relapse with Renal Outcomes under the Current Therapy Regimen for IgA Nephropathy: A Multi-Center Study.Lithium-Induced Minimal Change Disease and Acute Kidney Injury.Acthar gel in the treatment of nephrotic syndrome: a multicenter retrospective case series.Activation of the IL-2 Receptor in Podocytes: A Potential Mechanism for Podocyte Injury in Idiopathic Nephrotic Syndrome?The Evidence-Based Approach to Adult-Onset Idiopathic Nephrotic Syndrome.Minimal change nephrotic syndrome associated with non-Hodgkin lymphoid disorders: a retrospective study of 18 cases.Clinical outcomes and predictors for ESRD and mortality in primary GN.Fibrinogen excretion in the urine and immunoreactivity in the kidney serves as a translational biomarker for acute kidney injury.Comparative differential proteomic analysis of minimal change disease and focal segmental glomerulosclerosis.Proteinuria predicts relapse in adolescent and adult minimal change disease.Acute tubular necrosis and renal failure in patients with glomerular disease.Complete Remission in the Nephrotic Syndrome Study Network.Complete remission induced by tacrolimus and low-dose prednisolone in adult minimal change nephrotic syndrome: A pilot study.Haematuria on the Spanish Registry of Glomerulonephritis.Clinical-Morphological Features and Outcomes of Lupus PodocytopathyPredictors of Relapse in Adult-Onset Nephrotic Minimal Change Disease.Effective treatment with rituximab for the maintenance of remission in frequently relapsing minimal change disease.
P2860
Q24202262-15CEE1B6-0F7F-4D97-81AE-4ADA441C8F39Q24632899-DBAF2961-B793-4710-B06C-B98C12524D4AQ30409953-8F3F83A5-57D4-422D-848F-425696C49EF7Q33168844-06C4F9EB-E096-4EBB-85F2-78E22F4306AFQ33485544-09FCD595-66AA-4718-A8F8-016621782461Q33571864-60162907-4D72-4ABB-BFA5-DA42E4B87A9DQ33601648-4841A0B1-457C-40B9-BB0D-70CFAA7C5229Q33697151-4AB32BF6-2B05-4D12-A88D-95EFDD8E5BA8Q33715857-53706C8A-934F-4B7D-BCFB-3D903EB25DD1Q33715862-05D837AA-5E98-4F85-9204-6BE9AA8B1562Q33793403-CAD8594B-A4D3-4A30-86A8-3511781D1544Q34177446-D93B557C-F166-4974-A678-6CA6CA0CB97AQ34298085-C94C1644-C207-4660-B623-05A29E0F4B7FQ34324615-B7C202E3-87DD-4D08-B61B-04833125983FQ34455143-1489150B-5C9E-4074-9C65-FBCB8A31AB93Q34496366-C6DD2B62-072A-44AE-AB55-A46EF9816EA4Q34618530-321BE2A9-7371-419F-86F7-033E116F38A8Q35086137-4D88CE8E-DBE7-4A0E-B04F-482B0A3D18B4Q35227551-490C60F1-D9F6-4F22-B28B-384983319EC8Q35546991-E9A0BBAE-F687-42BD-B23F-7789088BA76DQ35626525-29B7749E-D183-4F5E-9709-562101508374Q35674857-4C191C18-BE47-4F9C-A0BA-D631C368653AQ35767979-A49C5B1A-A89A-4FCD-8A42-FA5D33E91B1DQ35775659-8D5BF1FD-FEBA-4179-8582-E23F5AE8639EQ35917758-97E4EDF4-9222-422D-A62F-A1F79B343DCAQ35976834-60332453-99F9-405B-B0BB-A49CAD8B03DCQ36070424-4829DE58-EFE4-4128-AB20-790858DE4E06Q36098017-79D51563-7C4E-4489-A88A-C3DFE23DEB10Q36150869-1069E5E8-E58C-4A2C-8DC0-88E406B61A10Q36199569-7E6DD466-EFB6-4C60-AD37-C6E7AFB52D3DQ36204158-F30AA02C-77C9-41FD-B4D6-3970840ED548Q36270335-D3C42223-3869-455A-8AF5-60ACA7108959Q36371221-A1FC48F7-E96E-4259-A7D9-60C564E9830EQ36393371-C2CB4C90-B7E3-4930-9800-7FA8FF37E447Q36432859-0072B4AC-D9A3-42DC-8CBB-5B0D67FEB5F2Q36468653-AF344B8E-BF1C-4033-92D1-9E76B2AE27AEQ36511959-BFDE6DDF-59BE-4231-AAAB-E02A359548E3Q36770865-9066D243-6E86-4220-83EF-D0958FA93341Q37205447-CDDA5FEF-AE93-4031-9610-D018C1409444Q37261621-DD5DAD91-7022-4E99-A8F4-725A99D485FF
P2860
Adult minimal-change disease: clinical characteristics, treatment, and outcomes.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Adult minimal-change disease: clinical characteristics, treatment, and outcomes.
@en
type
label
Adult minimal-change disease: clinical characteristics, treatment, and outcomes.
@en
prefLabel
Adult minimal-change disease: clinical characteristics, treatment, and outcomes.
@en
P2093
P356
P1476
Adult minimal-change disease: clinical characteristics, treatment, and outcomes
@en
P2093
Anthony Valeri
Gerald Appel
Glen Markowitz
Joshua Busch
Meryl Waldman
R John Crew
Vivette D'Agati
P304
P356
10.2215/CJN.03531006
P577
2007-04-11T00:00:00Z